IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · IEX Real-Time Price · USD
0.746
-0.014 (-1.79%)
At close: Jul 19, 2024, 4:00 PM
0.720
-0.026 (-3.55%)
Pre-market: Jul 22, 2024, 9:08 AM EDT
IceCure Medical Employees
As of December 31, 2023, IceCure Medical had 77 total employees, including 71 full-time and 6 part-time employees. The number of employees increased by 5 or 6.94% compared to the previous year.
Employees
77
Change (1Y)
5
Growth (1Y)
6.94%
Revenue / Employee
$42,364
Profits / Employee
-$188,221
Market Cap
35.78M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77 | 5 | 6.94% |
Dec 31, 2022 | 72 | 8 | 12.50% |
Dec 31, 2021 | 64 | 17 | 36.17% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
DarioHealth | 294 |
Achilles Therapeutics | 215 |
Aadi Bioscience | 89 |
Precision Optics Corporation | 85 |
Xilio Therapeutics | 73 |
iCAD, Inc. | 69 |
IGC Pharma | 67 |
Cue Biopharma | 53 |
ICCM News
- 56 minutes ago - 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society - PRNewsWire
- 2 days ago - IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 13 days ago - European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer - PRNewsWire
- 21 days ago - U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes - PRNewsWire
- 4 weeks ago - IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 - PRNewsWire
- 5 weeks ago - Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function - PRNewsWire
- 6 weeks ago - FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan - PRNewsWire
- 7 weeks ago - IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 - PRNewsWire